| Literature DB >> 20125171 |
Abstract
Minimizing the potential adverse effects of clinical investigators' financial conflicts of interest involves, in part, determining how much of an investigator's "business" should be disclosed to participants in research studies. What should be disclosed and why? How will we know if disclosure matters?Entities:
Mesh:
Year: 2010 PMID: 20125171 DOI: 10.1038/nrrheum.2009.264
Source DB: PubMed Journal: Nat Rev Rheumatol ISSN: 1759-4790 Impact factor: 20.543